Q3 EPS Estimates for CVS Health Boosted by Leerink Partnrs

Key Points

• CVS Health's EPS estimates for Q3 2025 have been increased to $1.35 per share by Leerink Partners, slightly higher than previous estimates.
• The company reported a significant revenue increase of 8.4% year-over-year, with current quarter revenue of $98.92 billion, surpassing the consensus estimate of $94.87 billion.
• CVS Health will pay a quarterly dividend of $0.665 per share on November 3rd, resulting in an annualized dividend yield of 3.2%.

CVS Health Corporation (NYSE:CVS - Free Report) - Stock analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for CVS Health in a research report issued to clients and investors on Thursday, October 16th. Leerink Partnrs analyst M. Cherny now expects that the pharmacy operator will post earnings of $1.35 per share for the quarter, up from their prior forecast of $1.34. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Leerink Partnrs also issued estimates for CVS Health's Q4 2025 earnings at $0.99 EPS.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter in the previous year, the firm posted $1.83 earnings per share. CVS Health's revenue for the quarter was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS.

A number of other equities research analysts have also weighed in on the stock. Baird R W raised shares of CVS Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Barclays boosted their price objective on shares of CVS Health from $80.00 to $87.00 and gave the company an "overweight" rating in a report on Thursday, September 4th. Zacks Research lowered shares of CVS Health from a "strong-buy" rating to a "hold" rating in a report on Monday, September 8th. UBS Group upgraded CVS Health from a "neutral" rating to a "buy" rating and upped their target price for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Finally, Mizuho upped their target price on CVS Health from $76.00 to $88.00 and gave the stock an "outperform" rating in a research note on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus target price of $82.57.

CVS Health Price Performance

NYSE CVS opened at $82.64 on Monday. The firm's fifty day simple moving average is $74.00 and its two-hundred day simple moving average is $68.12. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. CVS Health has a 12-month low of $43.56 and a 12-month high of $82.88. The firm has a market capitalization of $104.81 billion, a P/E ratio of 23.08, a P/E/G ratio of 0.91 and a beta of 0.60.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health's dividend payout ratio is presently 74.30%.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the transaction, the director owned 22,156 shares in the company, valued at $1,573,519.12. This represents a 25.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.22% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Ethic Inc. raised its position in shares of CVS Health by 13.8% during the 3rd quarter. Ethic Inc. now owns 38,187 shares of the pharmacy operator's stock worth $2,879,000 after purchasing an additional 4,636 shares during the last quarter. Sunburst Financial Group LLC acquired a new position in shares of CVS Health during the 3rd quarter worth about $218,000. Perigon Wealth Management LLC raised its holdings in CVS Health by 126.0% in the 3rd quarter. Perigon Wealth Management LLC now owns 33,853 shares of the pharmacy operator's stock valued at $2,552,000 after acquiring an additional 18,872 shares during the last quarter. Thompson Investment Management Inc. raised its holdings in CVS Health by 1.8% in the 3rd quarter. Thompson Investment Management Inc. now owns 127,669 shares of the pharmacy operator's stock valued at $9,625,000 after acquiring an additional 2,297 shares during the last quarter. Finally, Mayflower Financial Advisors LLC raised its holdings in CVS Health by 9.4% in the 3rd quarter. Mayflower Financial Advisors LLC now owns 9,331 shares of the pharmacy operator's stock valued at $703,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.